PBAC's latest decision on Mercaptopurine: Recommended (2014). Considered for Treatment of acute lymphoblastic leukaemia in paediatric patients when the tablet form is unsuitable.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Paediatric patients with acute lymphoblastic leukaemia for whom the solid dose form of mercaptopurine is unsuitable.
Therapy area
Haematology
Line of therapy
Any
Evidence base
Single-arm
Primary endpoint
Cost-minimisation
Comparator
mercaptopurine 50 mg tablets
Economic model
Cost-minimisation
ICER note
Cost-analysis presented for financial implications only; no ICER calculated (minor submission).